PharmaKure, a clinical stage company developing precision medicine for Alzheimer’s and other neurodegenerative diseases, has announced a research collaboration agreement with the Faculty of Pharmacy in Universiti Teknologi MARA (UiTM), one of the largest comprehensive universities in Malaysia. The partnership is focused on advancing research initiatives on the use of machine learning tools to predict Alzheimer’s disease using blood via academic-industry partnerships.
The new relationship aims to translate clinical research from UiTM using PharmaKure’s novel whole blood testing and machine learning technology for identifying early-stage Alzheimer’s disease to support the development of much needed diagnostic tests worldwide. Pharmakure recently announced a successful study for its proprietary ALZmetrix blood-based biomarker test, which together with its machine learning tools can predict which biomarkers are most useful in detecting people at high risk of developing Alzheimer’s disease. A simple whole blood test such as ALZmetrix may offer an accurate and simple alternative to expensive and invasive PET brain imaging or cerebrospinal fluid (CSF) collection.
"The UK has an ageing population, where 1 in 14 people over the age of 65 have Alzheimer’s disease. There is an urgent need to not only identify people who will develop this devasting disease, but also develop treatments. This agreement marks a significant milestone in establishing a research collaboration with UiTM, a leading academic institute, allowing us to partner with key experts and enhance our in-house expertise in the analysis of molecular signatures of disease biomarkers associated with Alzheimer’s,” said Dr Farid Khan, CEO of PharmaKure.
Professor Dato’ Dr Abu Bakar Abdul Majeed, Dean of Pharmacy Faculty in UiTM said: "Malaysia is expected to be an ageing nation by 2030, with almost half a million dementia patients predicted in 2050. That’s why this research partnership is important; we want to drive innovation and have societal impact both here and across the rest of the world. Alzheimer’s is a complex disease, by combining UiTM’s and PharmaKure’s biomarker, clinical and imaging data together with machine learning algorithms we will gain better understanding of how this disease develops and ultimately find ways to treat it.”
For more information, visit the Pharmakure website www.pharmakure.com.
